

Original Research Article

IMPACT OF CENTRAL AORTIC PRESSURES ON LEFT VENTRICULAR MASS INDEX

ABSTRACT

AIMS: .To measure central aortic pressures using Brachial cuff pulse volume plethysmography (PVP) and left ventricular mass index by echocardiography using standard DEVEREUX & REICHEK CUBE and BSA in hypertensive patients.To correlate central aortic and brachial cuff pressures with the left ventricular mass in hypertensive patients.

STUDY DESIGN: cross-sectional, observational study.

PLACE AND DURATION OF STUDY: From september 2018 to july 2020 at G Kuppuswamy Naidu Memorial Hospital, Coimbatore, Chennai.

METHODOLOGY: A total of 228 patients were included in the study, their written informed consent were obtained.With the help of a structured questionnaire basic demographic profile of the systemic hypertension patients such as Age, Gender, Family history of hypertension/CAD , smoking, duration of hypertension, number of hypertensive medications patient is on and other comorbid conditions, electrocardiogram, previous Echocardiogram if available were recorded. Newly detected hypertensives satisfying AHA/ACC definition and hypertensives fulfilling inclusion criteria were included. Patients who are satisfying inclusion criteria were subjected for measurement of Central aortic blood pressures, peripheral blood pressures, mean pulse wave velocity & augmentation index measured using noninvasive brachial oscillometry with a Mobil-O-Graph PWA device -ARC slover (IEM GmbH).Using Philips EPIQ 7 Cardiac ultrasound machine baseline transthoracic echocardiogram, Left ventricular mass index assessment by a linear method using DEVEREUX & REICHEK CUBE formula of patients was recorded. Data compiled and the statistical analysis done.

RESULTS:

We analysed 228 selected hypertensive subjects, and our observations were increased age (> 50 years), smoking, increased duration of hypertension (> 2 years), obesity, very high central Aortic Systolic, and Diastolic Pressure, high Mean Pulse Wave Velocity, and patients on Non (CCB + ACEI + ARB) group of hypertensive drugs were found to be an independent predictor for abnormal LVMI in hypertensive patients, which could be an early marker of myocardial dysfunction, major cardiovascular events and death. central Aortic pressure (aortic systolic and diastolic pressure) was found to be the strongest predictor of abnormal LVMI among hypertensive patients in our study followed by Mean Pulse Wave Velocity.

CONCLUSION

Elevated central aortic pressures measured non-invasively by brachial cuff pulse volume plethysmography in hypertensive individuals are associated and statistically correlated with an increase in LVMI.

KEY WORDS : Central Aortic Pressures (CAP), Left Ventricular Mass (LVM) , Mean Pulse Wave Velocity (aPWV), Left ventricular mass index (LVMI), brachial cuff pressures, Augmentation index, Hypertension.

INTRODUCTION:

Hypertension is the leading cause of death and disability worldwide ^{1,2}. The use of a sphygmomanometer for measuring brachial artery pressures was introduced into medical practice well over ten decades ago, which enabled the routine non-invasive measurement of arterial blood pressure. Data from RCTs over the last fifty years demonstrates that lowering blood pressure in hypertensive individuals, reduces major cardiovascular events ^{1,3} substantially. It's well known that systolic pressure varies throughout the arterial tree, such as the measured central aortic pressure (CAP) is lower than the corresponding brachial values, although this difference has high variability between individuals. ^{1,2} Over the last 5 decades, studies have clearly shown that CAP compared to brachial cuff pressures is a better predictor of cardiovascular events ^{4,5}, and it responds differently to certain drugs ^{6,7}. CAP acts as a key factor over hemodynamic changes that affect myocardial muscle ⁴. With the advent of new applanation tonometer's & brachial cuff pulse volume plethysmography, central aortic pressures (CAP) can now be assessed non-invasively with the same ease as brachial pressures ⁸. CAP is derived using peripheral pulse waveforms typically of brachial or radial arteries ^{9,10}. CAP is more closely correlated with the wide accepted surrogate of left ventricular mass (LVM) ^{11,12} and carotid intimal medial thickness ¹³. Hypertrophy of the left ventricle can be a marker for vascular injury in hypertensives. Studies have shown that regression of LVM was more strongly related to change in central pressures when compared with brachial pressures ^{11,12}. Several longitudinal observations provide greater support for the potential value of CAP measurement and its impact on LVM as well as hypertension drug optimization. ^{11,12}

METHODOLOGY

Based on inclusion and exclusion criteria, about 228 patients were included in the study. Written informed consent from the eligible patients or their legal representatives were obtained, the data of the patients were collected with the help of a structured questionnaire, which was filled up after interviewing the patients or his/her family members. Basic demographic profile of the systemic hypertension patients such as Age, Gender, Family history of hypertension/CAD, smoking, duration of hypertension, number of hypertensive medications patient is on, and other comorbid conditions were recorded. Previous blood pressure recordings, Electrocardiogram, previous Echocardiogram if available, were recorded. Newly detected hypertensives satisfying AHA/ACC definition and hypertensives fulfilling inclusion criteria were included. Patients who are satisfying inclusion criteria were subjected for measurement of Central aortic

blood pressures, peripheral blood pressures, mean pulse wave velocity & augmentation index measured using noninvasive brachial oscillometry with a Mobil-O-Graph PWA device -ARC slover (IEM GmbH). Using Philips EPIQ 7 Cardiac ultrasound machine, baseline transthoracic echocardiogram of patients was recorded. Left ventricular mass index assessment by a linear method using DEVEREUX & REICHEK CUBE formula and Body surface area were measured. The formula used for estimation of LVM from LV linear dimensions is based on modeling the LV as a prolate ellipse, assumed that the major/minor axis ratio is 2: 1. The upper limits of normal ranges in the ASE chamber quantification update are $>95 \text{ g/m}^2$ in women and $>115 \text{ g/m}^2$ in men. Data compiled and the statistical analysis was done.

RESULTS AND DISCUSSIONS:

We analysed 228 selected hypertensive subjects who were divided into two major groups, group-1 includes individuals with normal LV mass and group-2 includes persons with increased LV mass. Group -1 had 163 participants (71.49%) with a mean of 89.12 g/m^2 and Group-2 had 65 participants (28.51%) with a mean of 126.09 g/m^2 . Group-2 was subdivided based on outcome variable- based on the European Association of Cardiovascular Imageing classification: Mildly abnormal (n=30, 46.15%), Moderately abnormal (n=20, 30.77%) and Severely abnormal (n=15, 23.08%).

The age distribution analysis showed that in Group -1 the majority were in the 51-60 years age group (n=58, 35.58%) followed by the 41-50 years age group (n=48, 29.45%) with a mean age of 51.32 years. In Group -2 the majority of the subjects belonged to the 51-60 years age group (n=20, 30.77%) followed by the 41-50 years age group (n=19, 29.23%) with a mean age of 56.88 years. The association between age distribution among study groups is considered to be statistically significant. In group -2 as patient age increases the LVMI also increases, moderately correlated with age ($r = 0.512$, $P < 0.004$). Males were predominant in both groups with no statistical significance related to gender. Incidence of premature CAD, diabetes mellitus, dyslipidemia, pulse rate, hemodynamic parameters like peripheral SBP, peripheral DBP, and Augmentation Index showed no significant difference and effects on outcomes. The mean LVMI distribution was seen to be less among non-smokers compared to smokers (92.62 vs 105.64). The association between smoking status and incidental increase in LVMI was noted with statistical significance.

The majority of Group -1 subjects belonged to less than 2 years duration of hypertension (n=102, 50.25%) with a mean duration of hypertension of 4.58 years and Group-2 subjects belonged to 2-5 years duration of hypertension (n=46, 50.55%) with a mean duration of hypertension of 6.26 years. Increase in LVMI was positively correlated with duration of hypertension ($r = 0.694$, $P < 0.05$). The majority of Group 1 subjects belonged to the overweight class interval (n=85, 52.15%) and the majority of Group -2 subjects belonged overweight and obese class interval (n=27, 41.54%). The increase in LVMI was positively but moderately correlated with BMI ($r = 0.576$, $P < 0.044$).

Figure – 1 Correlation of Hemodynamic Parameters

Figure – 2 Correlation of Hypertension Drug Intake with Hemodynamic Parameters

It was observed that the mean values were correlating with central Aortic Systolic Pressure (124.02 vs 130.75), central Aortic Diastolic Pressure (90.56 vs 94.25), and Mean Pulse Wave Velocity (7.82 vs 8.68). There was an association between LVMI and central Aortic Systolic Pressure /Aortic Diastolic Pressure/ Mean Pulse Wave Velocity among study groups **is considered to be statistically significant. Comparing the different hypertension drug intake groups with key hemodynamic parameters showed that the mean values were smaller in no medicines group when compared CCB + ACEI + ARB group** which was smaller than non CCB + ACEI + ARB group concerning Aortic Systolic Pressure (126.05 vs 125.80 vs 126.09), Aortic Diastolic Pressure (90.40 vs 91.19 vs 92.41) and Augmentation Index (27.35 vs 23.47 vs 23.85). There was no association observed between hypertensive medications and **the Aortic Systolic Pressure/ Aortic Diastolic Pressure/Augmentation Index. The mean values were smaller in no medicines group when compared to CCB + ACEI + ARB group** which was smaller than non CCB + ACEI + ARB group in relation to Mean Pulse Wave Velocity (7.48 vs 7.88 vs 8.42) and LVMI (91.59 vs 93.50 vs 100.34). It was observed that there was an association between hypertensive medications and mean pulse wave velocity, LVMI among the study groups with statistical significance. The LVMI was positively but strongly correlating with central aortic systolic pressure ($r = 0.727$, $P < <0.001$) & central Aortic Diastolic Pressure ($r = 0.673$, $P < <0.001$). The LVMI was positively but very poorly correlating with Augmentation Index ($r = 0.172$, $P < 0.281$). The LVMI was positively but highly correlating with Mean aortic Pulse Wave Velocity ($r = 0.699$, $P < <0.001$), **table 1.**

TABLE-1 MULTIVARIABLE ANALYSIS – INDEPENDENT PREDICTORS OF ABNORMAL LVMI INHYPERTENSIVES

Parameter	HR	95% CI	P value
Age	2.07	1.04 to 4.09	< 0.001
Gender	1.67	1.03 to 3.09	0.526
Premature CAD	1.02	0.32 to 1.97	0.783
Smoking	1.67	1.01 to 3.78	0.017
Duration of Hypertension	2.24	1.04 to 4.83	< 0.001
Diabetes Mellitus	1.10	1.03 to 1.17	0.419
Dyslipidemia	1.05	0.94 to 1.07	0.875

BMI	2.76	1.24 to 4.78	< 0.001
Pulse Rate	1.56	1.08 to 1.84	0.187
Peripheral SBP	1.02	1.01 to 1.10	0.256
Peripheral DBP	1.03	0.99 to 1.06	0.224
Central Aortic Systolic Pressure	4.02	2.68 to 6.41	< 0.001
Central Aortic Diastolic Pressure	3.65	2.53to 5.59	< 0.001
Augmentation Index	1.20	1.07 to 1.35	0.343
Mean Pulse Wave Velocity(aPWV)	3.26	1.40 to 5.37	< 0.001
Hypertension Drug Intake – Non (CCB + ACEI + ARB)	2.70	1.26 to 4.34	0.018

Legend> HR,etc.

In summary, increased age (> 50 years), smoking, increased duration of hypertension (> 2 years), obesity, very high central Aortic Systolic, and Diastolic Pressure, high Mean Pulse Wave Velocity, and patients on Non (CCB + ACEI + ARB) group of hypertensive drugs were found to be an independent predictor for abnormal LVMI in hypertensive patients, which could be an early marker of myocardial dysfunction, major cardiovascular events and death. central Aortic pressure (aortic systolic and diastolic pressure) was found to be the strongest predictor of abnormal LVMI among hypertensive patients in our study followed by Mean Pulse Wave Velocity.

CONCLUSIONS

Elevated central aortic pressures measured non-invasively by brachial cuff pulse volume plethysmography in hypertensive individuals are associated and statistically correlated with an increase in LVMI. Elevated Mean pulse wave velocity in hypertensive individuals measured non-invasively by brachial cuff pulse volume plethysmography is associated and statistically correlated with an increase in LVMI. Even though age, sex, duration of hypertension, BMI were found to be independent predictors for LVMI, CAP and aPWV were found to have the strongest influence. The use of CCB as an antihypertensive agent as monotherapy or in combination with ACE/ARB was seen to be significantly associated with decreased LVMI and aPWV.

RECOMMENDATION:

- The routine measure of central aortic pressures non-invasively by approved devices (radial tonometers or brachial cuff PVP or supra systolic brachial cuff PVP) in hypertensive individuals with aids in better prognostication prevention of end-organ damage and medication optimization.

- Echocardiographic assessment of LVMI in all hypertensive subjects and periodic follow up of LVMI by echo imaging, preventing early onset of CV events.

COMPETING INTERESTS

Here I am enclosing my conflict of interest statement stating, that my study impact of central aortic pressures on left ventricular mass index, is approved by institutional ethical committee and scientific committee. My study does not include any funding nor any patient, animal harm. All patients were included after informed consent.

REFERENCES

1. McEnery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. *European heart journal*. 2014 Jul 7;35(26):1719-25.
2. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, Menard J, Mallion JM. Cardiovascular prognosis of masked hypertension detected by blood pressure self-measurement in elderly treated hypertensive patients. *Jama*. 2004 Mar 17;291(11):1342-9.
3. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003;362:1527-35.
4. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. *Hypertension*. 2007 Jul 1;50(1):197-203.
5. Pini R, Cavallini MC, Palmieri V, Marchionni N, Di Bari M, Devereux RB, Masotti G, Roman MJ. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. *Journal of the American College of Cardiology*. 2008 Jun 24;51(25):2432-9.
6. Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Loster M, Kloch-Badelek M, Wiliński J, Curyło AM, Dudek D. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. *Hypertension*. 2008 Apr 1;51(4):848-55.
7. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFÉ investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation*. 2006 Mar 7;113(9):1213.
8. Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. *Hypertension*. 2001 Oct 1;38(4):932-7.

9. Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. *Hypertension Research*. 2007 Mar;30(3):219-28.
10. Guilcher A, Brett S, Munir S, Clapp B, Chowienczyk PJ. Estimating central SBP from the peripheral pulse: influence of waveform analysis and calibration error. *Journal of hypertension*. 2011 Jul 1;29(7):1357-66.
11. Roman MJ, Okin PM, Kizer JR, Lee ET, Howard BV, Devereux RB. Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study. *Journal of hypertension*. 2010 Feb 1;28(2):384-8.
12. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. *Journal of hypertension*. 2004 Aug 1;22(8):1623-30.
13. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD. 2020 International Society of Hypertension global hypertension practice guidelines. *Hypertension*. 2020 Jun;75(6):1334-57.
14. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. *Hypertension*. 2007 Jul 1;50(1):197-203.
15. Rackley CE, Dodge HT, COBLE JR YD, Hay RE. A method for determining left ventricular mass in man. *Circulation*. 1964 May;29(5):666-71.
16. DEAGUE JA, WILSON CM, GRIGG LE, HARRAP SB. Discrepancies between echocardiographic measurements of left ventricular mass in a healthy adult population. *Clinical Science*. 1999 Sep 1;97(3):377-83.
17. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. *Circulation*. 1977 Apr;55(4):613-8.
18. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *European Heart Journal-Cardiovascular Imaging*. 2015 Mar 1;16(3):233-71.

19. Reichek NA, Helak JO, Plappert TH, Sutton MS, Weber KT. Anatomic validation of left ventricular mass estimates from clinical two-dimensional echocardiography: initial results. *Circulation*. 1983 Feb;67(2):348-52.
20. Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, Gottdiener J, Haluska B, Ofili E, Segers P, Senior R. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). *European Heart Journal-Cardiovascular Imaging*. 2015 Jun 1;16(6):577-605.
21. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. *Journal of the American College of Cardiology*. 1998 Nov 1;32(5):1454-9.
22. Turakhia MP, Schiller NB, Whooley MA. Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the Heart and Soul Study). *The American journal of cardiology*. 2008 Nov 1;102(9):1131-5.
23. McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. *European heart journal*. 2014 Jul 7;35(26):1719-25.
24. Safar ME, Blacher J, Protogerou A, Achimastos A. Arterial stiffness and central hemodynamics in treated hypertensive subjects according to brachial blood pressure classification. *Journal of hypertension*. 2008 Jan 1;26(1):130-7.
25. Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. *Hypertension*. 2001 Oct 1;38(4):932-7.
26. Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. Central or peripheral systolic or pulse pressure: which best relates to target-organs and future mortality?. *Journal of hypertension*. 2009 Mar;27(3):461.
27. Jankowski P, Kawecka-Jaszcz K, Czarnańska D, Brzozowska-Kiszka M, Styczkiewicz K, Loster M, Kloch-Badełek M, Wiliński J, Curyło AM, Dudek D. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. *Hypertension*. 2008 Apr 1;51(4):848-55.
28. Guleri N, Rana S, Chauhan RS, Negi PC, Diwan Y, Diwan D. Study of left ventricular mass and its determinants on echocardiography. *Journal of Clinical and Diagnostic Research: JCDR*. 2017 Sep;11(9):OC13.
29. F.J.Perez-Lahiguera et al. Relationship Between Central and Peripheral Arterial Pressure and Ventricular Mass left in hypertensive. *Rev Esp Cardiol*. 2012; 65(12) :1094–1100.

30. Krishna KS, Kiran MR, Garre I. Comparison of Derived Central Aortic Pressure vs Cuff Peripheral Pressure. *Indian Journal of Cardiovascular Disease in Women WINCARS*. 2017 Mar;2(01):020-5.
31. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Cheng S, Aragam J, Levy D, Benjamin EJ, Vasani RS, Mitchell GF. Relations of central hemodynamics and aortic stiffness with left ventricular structure and function: the Framingham Heart Study. *Journal of the American Heart Association*. 2016 Mar 25;5(3):e002693.
32. Kim HL, Lim WH, Seo JB, Kim SH, Zo ZH, Kim MA. The comparison of the impact of arterial stiffness and central pressure on left ventricular geometry and diastolic function. *Clinical hypertension*. 2019 Dec 1;25(1):18.
33. Salmasi AM, Alimo A, Jepson E, Dancy M. Age-associated changes in left ventricular diastolic function are related to increasing left ventricular mass. *American journal of hypertension*. 2003 Jun 1;16(6):473-7.
34. Maheshwari VD, Pillai A. Influence of smoking and hypertension on left ventricular mass. *The Journal of the Association of Physicians of India*. 2000 Apr;48(4):397.
35. Lønnebakken MT, Izzo R, Mancusi C, Gerds E, Losi MA, Cancelli G, Giugliano G, De Luca N, Trimarco B, de Simone G. Left ventricular hypertrophy regression during antihypertensive treatment in an outpatient clinic (the Campania Salute Network). *Journal of the American Heart Association*. 2017 Mar 8;6(3):e004152.
36. JAKOVLJEVIĆ B, Stojanov V, BELOJEVIĆ G, MATIĆ DC, LOVIĆ D. Left ventricular hypertrophy in obese hypertensive men. *International Journal of Cardiology*. 2009 Oct 1;137:S80-1.
37. Gupta RK, Gupta R, Makar N, Chaudhary S, Bhatheja H, Pathak P. The association of left ventricular mass index with metabolic syndrome in comparison to hypertensive patients. *Journal of cardiovascular echography*. 2016 Apr;26(2):42.
38. Pérez-Lahiguera FJ, Rodilla E, Costa JA, Gonzalez C, Martín J, Pascual JM. Relationship of central and peripheral blood pressure to left ventricular mass in hypertensive patients. *Revista Española de Cardiología (English Edition)*. 2012 Dec 1;65(12):1094-100.
39. Choi CU, Kim EJ, Kim SH, Shin SY, Choi UJ, Kim JW, Lim HE, Rha SW, Park CG, Seo HS, Oh DJ. Differing effects of aging on central and peripheral blood pressures and pulse wave velocity: a direct intraarterial study. *Journal of hypertension*. 2010 Jun 1;28(6):1252-60.
40. Shin J, Choi BY, Yamori Y, Lee Y, Kim BK, Choi SY, Mori M. [PP. 37.20] THE RELATIONSHIP BETWEEN CENTRAL BLOOD PRESSURE AND LEFT VENTRICULAR MASS INDEX IN COMPARISON WITH CASUAL AND AMBULATORY BLOOD PRESSURES. *Journal of Hypertension*. 2016 Sep 1;34:e347.

41. Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. Central or peripheral systolic or pulse pressure: which best relates to target-organs and future mortality?. *Journal of hypertension*. 2009 Mar;27(3):461.
42. de la Sierra A, Pareja J, Yun S, Acosta E, Aiello F, Oliveras A, Vázquez S, Armario P, Blanch P, Sierra C, Calero F. Central blood pressure variability is increased in hypertensive patients with target organ damage. *The Journal of Clinical Hypertension*. 2018 Feb;20(2):266-72.
43. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ, Camelot Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. *Jama*. 2004 Nov 10;292(18):2217-25.
44. Manisty CH, Zambanini A, Parker KH, Davies JE, Francis DP, Mayet J, McG Thom SA, Hughes AD. Differences in the magnitude of wave reflection account for differential effects of amlodipine-versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome Trial substudy. *Hypertension*. 2009 Oct 1;54(4):724-30.
45. Hametner B, Wassertheurer S, Kropf J, Mayer C, Eber B, Weber T. Oscillometric estimation of aortic pulse wave velocity: comparison with intra-aortic catheter measurements. *Blood pressure monitoring*. 2013 Jun 1;18(3):173-6.
46. Litwin M, Obrycki Ł, Niemirska A, Sarnecki J, Kułaga Z. Central systolic blood pressure and central pulse pressure predict left ventricular hypertrophy in hypertensive children. *Pediatric Nephrology*. 2019 Apr 1;34(4):703-12.
47. Brett SE, Guilcher A, Clapp B, Chowienczyk P. Estimating central systolic blood pressure during oscillometric determination of blood pressure: proof of concept and validation by comparison with intra-aortic pressure recording and arterial tonometry. *Blood pressure monitoring*. 2012 Jun 1;17(3):132-6.
48. Baba BA, Johan PT, Mohan JC. Comparison of central aortic pressure to brachial artery pressure in hypertensive patients on drug treatment: An observational study. *Indian heart journal*... incomplete...
49. Na J, Kim E, Lim S, Choi C, Lim H, Rha S, Park C, Seo H, Oh D. The relationship between central aortic pressure, brachial blood pressure and left ventricular mass index: in first diagnosed hypertensive patients: PP. 29.164. *Journal of Hypertension*. 2010 Jun 1;28:e498

These articles are not cited in the manuscript